Allscripts Announces Corporate Name Change to Veradigm Inc.
04 January 2023 - 8:01AM
Business Wire
Allscripts Healthcare Solutions, Inc. announced today that,
effective January 1, 2023, it has changed its name to Veradigm Inc.
(NASDAQ: MDRX). Allscripts had been transitioning its solutions to
the Veradigm brand during 2022, and Allscripts will now formally be
known as Veradigm.
The US healthcare ecosystem – including healthcare providers,
biopharma, payers, and the government – is converging around the
shared goal of delivering a higher quality of patient care, more
economically. Transitioning away from disconnected, dysfunctional,
disparate systems, healthcare stakeholders are being driven toward
interoperable, open, and connected solutions. In the new healthcare
landscape, community-based, diverse data derived from the point of
patient care can be translated into actionable insights, driving
measurable value, and supporting a higher quality of care.
Veradigm connects over 300,000 US healthcare providers via the
Veradigm Network, helping to facilitate the transition to
value-based care, while representing over 170 million patients.
Through its significant healthcare provider base, the Veradigm
Network provides life science and health plan organizations unique
access to de-identified patient data, provider connectivity and
analytics at scale.
After more than two years of streamlining its corporate
portfolio, all remaining Allscripts assets including electronic
health records, practice management systems, and patient
communication platforms are now integrated into the Veradigm
Network, providing the connectivity needed to realize the vision of
improved patient outcomes achieved more economically.
“Some healthcare technology companies deliver clinical data for
biopharma and health plans, some help turn that data into insights,
others serve healthcare providers directly by providing
point-of-care clinical software and patient outreach platforms,
Veradigm does it all,” said Rick Poulton, Veradigm Chief Executive
Officer. “As our markets continue to evolve, completing our brand
transition to Veradigm represents a capstone on our own evolution
as a company. We are well-positioned to drive growth and serve each
market where we compete.”
About Veradigm®
Veradigm is a healthcare technology company that drives value
through its unique combination of platforms, data, expertise,
connectivity, and scale. The Veradigm Network features a dynamic
community of solutions and partners providing advanced insights,
technology, and data-driven solutions, all working together to
transform healthcare insightfully. For more information on
Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn,
Facebook, Twitter, and YouTube
© 2023 Veradigm Inc. and/or its affiliates. All rights
reserved.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our 2023 outlook, our
profitability initiatives, our strategic priorities and our client
outcomes. These forward-looking statements are based on the current
beliefs and expectations of Veradigm management, only speak as of
the date that they are made and are subject to significant risks
and uncertainties. Such statements can be identified by the use of
words such as “future,” “anticipates,” “believes,” “estimates,”
“expects,” “intends,” “plans,” “predicts,” “will,” “would,”
“could,” “can,” “may,” “look forward,” “pipeline” and similar
terms. Actual results could differ significantly from those set
forth in the forward-looking statements, and reported results
should not be considered an indication of future performance or
events.
Certain factors that could cause our actual results to differ
materially from those described in the forward-looking statements
include, but are not limited to: our ability to achieve the margin
targets associated with our margin improvement initiatives within
the contemplated time periods, if at all; the magnitude, severity,
duration and impacts of the COVID-19 pandemic, along with the
impacts of our responses and the responses by governments and other
businesses to the pandemic, on our business, our employees, our
clients and our suppliers; security breaches resulting in
unauthorized access to our or our clients’ computer systems or
data, including denial-of-services, ransomware or other
Internet-based attacks; the failure by Practice Fusion to comply
with the terms of the settlement agreements with the U.S.
Department of Justice (the “DOJ”); the costs and burdens of
compliance by Practice Fusion with the terms of its settlement
agreements with the DOJ; additional investigations and proceedings
from governmental entities or third parties other than the DOJ
related to the same or similar conduct underlying the DOJ’s
investigations into Practice Fusion’s business practices; our
ability to recover from third parties (including insurers) any
amounts paid in connection with Practice Fusion’s settlement
agreements with the DOJ and related inquiries; the expected
financial results of businesses acquired by us; the successful
integration of businesses acquired by us; the anticipated and
unanticipated expenses and liabilities related to businesses
acquired by us, including the civil investigation by the U.S.
Attorney’s Office involving our Enterprise Information Solutions
business; other risks associated with investments and acquisitions;
risks associated with disposition of the Hospitals and Large
Physicians Practices Business, our failure to compete successfully;
consolidation in our industry; current and future laws, regulations
and industry initiatives; increased government involvement in our
industry; the failure of markets in which we operate to develop as
quickly as expected; our or our customers’ failure to see the
benefits of government programs; changes in interoperability or
other regulatory standards; our ability to maintain and expand our
business with existing clients or effectively transition clients to
newer products; the effects of the realignment of our sales,
services and support organizations; market acceptance of our
products and services; the unpredictability of the sales and
implementation cycles for our products and services; our ability to
manage future growth; our ability to introduce new products and
services; our ability to establish and maintain strategic
relationships; risks associated with investments and acquisitions;
the performance of our products; our ability to protect our
intellectual property rights; the outcome of legal proceedings
involving us; our ability to hire, retain and motivate key
personnel; performance by our content and service providers;
liability for use of content; price reductions; our ability to
license and integrate third-party technologies; risks related to
global operations; variability of our quarterly operating results;
risks related to our outstanding indebtedness; changes in tax rates
or laws; business disruptions; our ability to maintain proper and
effective internal controls; and asset and long-term investment
impairment charges. Additional information about these and other
risks, uncertainties, and factors affecting our business is
contained in our filings with the Securities and Exchange
Commission, including under the caption “Risk Factors” in our most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Qs. We do not undertake to update forward-looking
statements to reflect changed assumptions, the impact of
circumstances or events that may arise after the date of the
forward-looking statements, or other changes in our business,
financial condition or operating results over time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230103005772/en/
Investors: Jenny Gelinas
312-506-1237 jenny.gelinas@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024